ArticleJournal of translational medicine2026
Mesenchymal stromal cell therapy for post-COVID-19 syndrome: associated impact and mechanism.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-COVID-19 syndrome (PCS) affects around 10% of individuals who experience SARS-CoV-2 infection worldwide. This four-year follow-up study investigated the long-term impact of mesenchymal stromal cell (MSC) therapy on both the occurrence of PCS and its underlying mechanisms.
methodsWe enrolled 148 survivors of severe COVID-19 (92 who received MSC therapy and 56 who served as controls). The clinical evaluations included safety (new-onset comorbidities, oncogenic risk) and efficacy outcomes (computed tomography [CT] imaging, functional capacity, pulmonary function, 36-Item Short-Form Survey [SF-36], PCS prevalence). Serum proteomic profiling was performed to identify the differentially expressed proteins (DEPs) across the PCS subtypes, including chronic fatigue-like syndrome (CFs), respiratory syndrome (REs), chronic pain syndrome (CPs), and neurosensorial syndrome (NSs).
resultsMSC therapy had a favorable long-term safety profile. The overall prevalence of PCS was 73.6% (109/148), with CFs being the most common subtype (50.7%, 75/148). Moreover, the incidence of CFs was significantly lower in the MSC group than in the control group (41.3% vs. 66.1%; odds ratio = 0.361, p = 0.003). MSC therapy was also associated with a significant improvement in the SF-36 Role-Emotional domain. No significant differences were observed in the participants’ CT outcomes, functional capacity, or pulmonary function. A predictive model integrating proteomic and clinical data for CFs achieved an area under the curve of 0.773. Unsupervised clustering identified three molecular endotypes, with one being both highly enriched for respiratory syndrome and characterized by dysregulated immune pathways.
conclusionThis 4-year follow-up shows a sustained association between MSC therapy and a lower likelihood of CFs in severe COVID-19 survivors, with a favorable safety profile. Integrated proteomic and clinical analysis reveals distinct biological pathways underpinning PCS heterogeneity, suggesting potential biological bases underlying the subtype-specific associations observed with MSC therapy and highlighting potential targets for future precision medicine approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.